David Andrews

David Andrews

Company: Imvax

Job title: Co-Founder, Chief Medical Officer


Special Look At Phase 1b Imvax Study to Assess the Safety and Efficacy of IGV-001 5:05 pm

Explore highest exposure cohort yielded significantly higher proinflammatory cytokine serum levels; by 23rd patient, clear that clinical and radiographic responses were superior in this cohort and protocol amended for ethical reasons to stop randomization. Deep dive with data lock, highest exposure cohort exhibiting significant improvement in both PFS and OS over historical controls. Study methylated…Read more

day: Day One

PANEL DISCUSSION: Lessons Learned from Failed and Discontinued Clinical Trials for the Treatment of Glioblastoma 5:45 pm

Debate the common challenges with moving GBM clinical trials forward What can we learn from the plethora of failed phase 2 trials? With a high failure rate of phase 3 glioblastoma trials, panellists examine the need for greater reliability of earlier studiesRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.